Pharmaceuticals, Biotechnology and Life Sciences
Amgen said in a press release Tuesday it’s total revenues decreased 3% to $5.7 billion compared with the same period last year, reflecting the impact of biosimilar and generic competition against key products.
Amgen and UCB said Friday that Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has re-examined and recommended Marketing Authorization for Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
Amgen’s Repatha will now be used as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Amgen and UCB on Tuesday reported getting licence to market Evenity to treat patients with osteoporosis, who have high risk…
The US Food and Drug Administration (FDA) has approved Novartis’s and Amgen’s Aimovig (erenumab) for the preventive treatment of migraine in…
Amgen’s Phase 3b study called Liberty, in co-development with Novartis, aimed to test Aimovig for treating migraine, has met it’s…
Novartis, Amgen and the Banner Alzheimer’s Institute (BAI) on Thursday revealed expanding collaboration to initiate a new trial on the…
AstraZeneca and Amgen on Thursday published results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. The trial results were published in the New England Journal of Medicine. The PATHWAY trial achieved its primary efficacy endpoint, showing annual asthma exacerbation rate reductions.
Amgen posted positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three years after enrollment.
Amgen and Novartis have formed a coalition that will be expanded and, as they hope, bring easier launching of a migraine related product, the USA-based company said late Monday.